ERBB2 and breast carcinoma: Attaching trastuzumab and folic acid targeting human epidermal growth factor receptor 2 (HER2) to 4.2 nm AuNCs, Roghayeh et al. demonstrated that the targeted AuNCs may infiltrate breast cancer SK-BR3 cells through HER-2-mediated mechanisms [110].